Tentarix Biotherapeutics announced four key executive changes that further strengthen its executive team and capabilities as it advances a differentiated pipeline into development. Ash Khanna, Ph.D., joins as Chief Business Officer; Dallas Jones, Ph.D., as Senior Vice President, Biology; and Tim Noffke as Vice President, Program Management and Chief of Staff. The Company also announced the promotion of Ankita Srivastava, Ph.D., to Senior Vice President, Biotherapeutics.

Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience.

AbbVie Inc. and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

Tentarix Biotherapeutics today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.

Gilead Sciences, Inc. and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.

Tentarix Biotherapeutics today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team.

Tentarix Biotherapeutics today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital.